29 August 2016

Sheeran shines on Romanian trials

James Crux

Brian Sheeran, chairman of green technology company Virotec, delivered some good news to investors today with exciting news of trials in Romania of its Bauxsol waste water cleaning technology.

Sheeran and Dr David McConchie, a fellow director and the group's chief scientific consultant, had just visited Baia Mare in Romania, joining other Virotec staff who were treating 3 million litres of Acid Mine Drainage (AMD) with the group's Bauxsol technology. 'We've had large enquiry levels from Europe', said Sheeran, 'and were invited to Baia Mare by Romanian mining company Remin to do trials'.

Formerly a mining venture Down Under, Virotec (VTI) has worldwide marketing and distribution rights to 'Bauxsol', a 'green' technology that neutralises acid and removes heavy metals from environmentally contaminated water. Although the actual results have not been released yet, McConchie hinted at positive news. 'The initial trials gave fantastic results', he added. 'Our aim at Virotec is not only to protect the environment but to do it in an economically appealing way that will save mining companies money'.

All of this should have impressed observers from the United Nations Environment Programme, the European Union in Brussels and the London Stock Exchange who attended the Romanian trials. Significantly, the pair also boasted that the United States EPA is also currently trialling the technology. 'Trials in the US should be completed by December and we're hopeful of gaining EPA approval for the product for America', said Sheeran.

Virotec, already quoted on the Australian Stock Exchange, listed on Aim in July following a placing of 27.5 million new shares at 14p raising £3.36 million net. 'We came to Aim to internationalise the technology and be first to market', explained Sheeran. W H Ireland was broker to the float.

Today the shares were unchanged at 12.25p.

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Retailers getting One View of their customers

One View listed on AIM via a reverse takeover back in March. It has developed software that provides retailers with a combined view of their customers history in both online and in-store shopping channels. This sort of digital engagement is a big opportunity for retailers to boost their sales.

Angle moves into the clinical trial stage

Angle is making good progress with its ‘Parsortix’ system which uses a precision-etched cassette to ‘sieve’ patient blood samples and capture cancerous tumour cells. The first major trial is now underway in ovarian cancer, led by the University of Vienna.

StatPro benefiting from a Revolution

StatPro shares have done well over the last month with the stock market giving the company credit for the growth in its new ‘Revolution’ product.

Tracsis signs key US deal

Transportation software specialist Tracsis has won a significant contract in the US. This looks like it could be a breakthrough which opens up the vast North American railroad market to this Leeds based company.

MedaPhor expands in ultrasound

MedaPhor came to the market two years ago and the £14 million market cap’s shares have done little since. However a couple of recent developments suggest they are worth keeping an eye on.

ScS sees no slowdown in sofas

ScS Group confirms it hasn't seen a slowdown in demand post-Brexit. Momentum has continued since the update in early June, with like-for-like sales order intake of 14.8 per cent for the first financial year ending in July.

More News